Evotec SEEvotec SE is widening its 2022 R&D collaboration SynaptixBio Ltdi to optimise and identify new antisense oligonucleotides to treat children with H-ABC leukodystrophy, a rare genetic myelin synthesis defect that shows similar symptoms such as multiple sclerosis.
Tag Archive for: SynaptixBio
At the end of May, Dr Uwe Meya took over as Chief Medical Officer at Oxford-based SynaptixBio.